{"id":19534,"date":"2023-05-26T10:48:33","date_gmt":"2023-05-26T10:48:33","guid":{"rendered":"https:\/\/clinlabint.com\/?p=19534"},"modified":"2023-05-26T10:54:26","modified_gmt":"2023-05-26T10:54:26","slug":"agilent-acquires-e-msion-and-their-exd-cell-technology","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/agilent-acquires-e-msion-and-their-exd-cell-technology\/","title":{"rendered":"Agilent acquires e-MSion and their ExD cell technology"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Agilent acquires e-MSion and their ExD cell technology<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Agilent acquires e-MSion and their ExD cell technology<\/h4>\n

Agilent Technologies has acquired e-MSion, an early-stage company behind the innovative electron capture dissociation (ECD) technology known as the ExD cell.<\/h3>\n

<\/p>\n

The ExD cell is a compact device for mass spectrometers that enables biological researchers to develop biotherapeutic products more quickly to treat disease. This is done by more comprehensively and precisely breaking the chemical bonds of complex biomolecules, enabling more complete, accurate, and detailed structural information to be obtained from them.<\/p>\n<\/div><\/section>
\n

Agilent acquires e-MSion and their ExD cell technology<\/div><\/div><\/div>
\n

\u201cThe talented team at e-MSion has created an important technology in accelerating biopharma development,\u201d said Jacob Thaysen, president of Agilent\u2019s Life Sciences and Applied Markets Group (LSAG). \u201cWe are excited to integrate the ExD cell into our portfolio of advanced workflows, instruments, and analytical solutions for biotherapeutic characterization and development. Our customers will see tangible benefits from these unmatched capabilities.\u201d<\/p>\n

The ExD cell is compatible with instruments common in many labs, such as Agilent\u2019s 6500 LC\/Q-TOF series, which will make this powerful characterization technology \u2013 previously limited to only a few high-end mass spectrometers \u2013 more accessible to a larger share of labs and biopharma researchers worldwide.<\/p>\n

In more technical terms, the ExD cell enables electron capture dissociation (ECD) and other modes of electron-induced fragmentation in benchtop mass spectrometers. Because of its superior characterization of larger proteins, protein fragments, and their amino-acid modifications, ECD is preferred over other dissociation techniques including collision-induced disso-ciation (CID), which is the dominant methodology used today. Agilent has worked closely with e-MSion for several years and has offered the company\u2019s ExD cell technology with its 6500 series since 2019. e-MSion was founded by Oregon State University scientists, who developed the ExD cell.<\/p>\n<\/div><\/section>
\n